Table 3.
Association of aberrantly co-expressed pS9GSK-3β and β-Catenin proteins with clinicohistopathological factors in patients with urothelial carcinoma of bladder
| Characteristics | pS9GSK-3β + β-Catenin (low membranous, no expression or N/C expression) (n = 28/90) |
| Age 60 (38-78) | P = 1.0 |
| < 60 | 11/28 |
| ≥ 60 | 17/28 |
| Stage | P = 0.01a |
| Non muscle invasive | 9/28 |
| Muscle invasive | 19/28 |
| Grade | P = 0.09 |
| Low grade | 6/28 |
| High grade | 22/28 |
| Type | P = 0.02a |
| Primary | 11/28 |
| Recurrent | 17/28 |
| Smoking/tobacco chewing | P = 0.04a |
| Yes | 17/28 |
| No | 9/28 |
| Unknown | 0/28 |
| Hematuria | P = 1.0 |
| Present | 23/28 |
| Unknown | 5/28 |
| Metastasis | P = 0.9 |
| Present | 1/28 |
| Absent | 27/28 |
Non parametric Mann Whitney U test was used to determine the P-values.
a
P values ≤ 0.05 are considered as significant. N/C expression: Nuclear/cytoplasmic expression.